⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VYGR News
Voyager Therapeutics, Inc. Common Stock
Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
globenewswire.com
VYGR
Voyager to Present at Upcoming Investor Conferences
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Voyager Reports Second Quarter 2026 Financial and Operating Results
globenewswire.com
VYGR
Voyager Reports Second Quarter 2026 Financial and Operating Results
globenewswire.com
VYGR
Form 8-K
sec.gov
VYGR
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
globenewswire.com
VYGR
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
globenewswire.com
VYGR